Adagene Announces Completion of Enrollment in Randomized Dose Optimization Phase 2 Trial of Muzastotug in Combination with KEYTRUDA® (pembrolizumab) in Microsatellite Stable Colorectal Cancer
GlobeNewswire • Nov 9, 2026
Read articleWhat Does Incyte (INCY) First Patient Dosing Mean For Its Colorectal Cancer Pipeline?
Simply Wall St. • Oct 31, 2026
Read articleAdagene Announces Dosing of First Patient in Phase 1 Study of Muzastotug in Combination with Incyte’s INCA33890 in Patients with Microsatellite Stable Colorectal Cancer
GlobeNewswire • Oct 28, 2026
Read articleAdagene to Participate in the Guggenheim Securities 3rd Annual Healthcare Innovation Conference
GlobeNewswire • Oct 27, 2026
Read articleAdagene Eyes Phase II Data for Masked CTLA-4 Therapy in MSS Colorectal Cancer
MarketBeat • Oct 25, 2026
Read articleAdagene Highlights SAFEbody Pipeline, ADG138 Clinical Launch and 2027 Catalysts
MarketBeat • Oct 16, 2026
Read article